Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.82
    -0.04 (-2.41%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Editas Medicine Inc (EDIT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Editas Medicine (EDIT) has a market cap of $334.92M and an enterprise value of $298.57M. Revenue grew 417.26% over the last 12 months from the 12 months before. Its share count is up 70.50% from a year earlier.

    Total Valuation

    Enterprise value is 10.85% below the market cap, as cash exceeds debt.

    Market Cap$334.92M
    Enterprise Value$298.57M
    Latest price (Nov 17, 2026)$1.82

    Key Dates

    The next earnings report is set for Mar 8, 2027, after the close.

    Next Earnings DateMar 8, 2027, after the close
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 28.76% in the quarter ended Sep 30, 2026 and grew 36.46% a year over 2 years.

    Shares Outstanding153.60M
    Shares Change (YoY)+70.50%
    Shares Change (QoQ)+28.76%
    Share Count Growth (2Y CAGR)+36.46%

    Valuation Ratios

    Sales and book value multiples are 5.4x and 3.3x. Its year-end P/S ranged from 4.5x to 92.4x from 2016 to 2025.

    P/S Ratio5.4x
    Forward P/S10.3x
    P/B Ratio3.3x

    Valuation history and multiples

    Price Statistics

    The stock is down 29.81% over 52 weeks and trades 29.46% below its 50-day average.

    Beta (1Y)2.36
    52-Week Change-29.81%
    1-Month Change-24.59%
    3-Month Change-43.85%
    6-Month Change-25.81%
    5-Year Change-92.73%
    10-Year Change-81.12%
    Total Return (1Y)-29.81%
    Total Return (3Y CAGR)-42.85%
    Total Return (5Y CAGR)-45.03%
    Return vs SPY (1Y)-41.90%
    Max Drawdown (1Y)-51.33%
    Max Drawdown (3Y)-91.18%
    Sharpe Ratio (1Y)-0.43
    Correlation with SPY (1Y)0.39
    50-Day Average$2.58
    200-Day Average$2.70
    52-Week Range$1.66 to $3.94
    RSI (14 Days)31.9
    Average Volume (20 Days)2.29M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.82x current liabilities, and total debt is 0.67x shareholder equity.

    Current Ratio2.82x
    Quick Ratio2.82x
    Debt / Equity0.67x
    Interest Coverage-27.52x

    Returns and Efficiency

    Return on invested capital is -42.31% over the last 12 months, against a 5-year average of -97.11%.

    Return on Equity (ROE)-85.45%
    Return on Assets (ROA)-32.92%
    Return on Invested Capital (ROIC)-42.31%
    ROA (5Y Average)-51.44%
    ROIC (5Y Average)-97.11%
    Asset Turnover0.25x
    Receivables Turnover9.88x

    Scores

    EDIT has an Altman Z-Score of -9.76, in the distress zone below 1.81, and a Piotroski F-Score of 0 of 9, in the weak band of 0 to 2.

    Altman Z-Score-9.76
    Altman Z ZoneDistress
    Piotroski F-Score0 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $51.65M over the last 12 months.

    Revenue$51.65M
    Revenue Growth (YoY)+417.26%
    Gross Profit$51.65M
    Operating Income-$75.59M
    Pretax Income-$72.22M
    Net Income-$72.22M
    Reported EPS (TTM)-$0.62

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 38.52% of the $219.41M in total assets.

    Cash and Equivalents$93.17M
    Total Debt$56.82M
    Net Cash$36.35M
    Net Cash Per Share$0.24
    Working Capital$130.39M
    Shareholder Equity$84.52M
    Book Value Per Share$0.55
    Total Assets$219.41M
    Total Liabilities$134.89M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$110.21M
    FCF Per Share-$0.72
    Depreciation and Amortization$2.53M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -146.35%.

    Gross Margin100.00%
    Operating Margin-146.35%
    Pretax Margin-139.82%
    Net Margin-139.82%

    Growth

    Revenue grew 27.15% a year over 3 years.

    Revenue Growth (3Y CAGR)+27.15%
    Revenue Growth (5Y CAGR)-14.89%
    Book Value Per Share Growth (2Y CAGR)-73.17%
    Tangible Book Per Share Growth (2Y CAGR)-73.17%

    Revenue and profit by year

    Dividends and Yields

    EDIT does not pay a dividend.

    Buyback Yield-47.86%
    Shareholder Yield-47.86%

    Peer Position

    Against 9 similar companies, EDIT has the 5th highest P/S.

    P/S Ratio5.4x vs 4.3x median
    ROIC-42.31% vs -23.38% median
    Revenue Growth (Trailing 4 Quarters, YoY)+417.26% vs -14.43% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -28.60% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-28.60%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EDIT

    What is EDIT's market cap?

    Editas Medicine has a market cap of $334.92M. Its enterprise value, which adds debt and subtracts cash, is $298.57M.

    How many shares of EDIT are outstanding?

    Editas Medicine has 153.60M shares outstanding. The count is up 70.50% from a year earlier.

    Does EDIT pay a dividend?

    No. Editas Medicine does not pay a dividend.

    How much debt does EDIT have?

    Editas Medicine has $56.82M of total debt and $93.17M of cash and equivalents, a net cash position of $36.35M.